LL-37
Human cathelicidin antimicrobial peptide. 37-amino acid cationic peptide with broad-spectrum antimicrobial and immune-modulating properties. Used for infections, biofilm disruption, and wound healing.
Overview
Human cathelicidin antimicrobial peptide. 37-amino acid cationic peptide with broad-spectrum antimicrobial and immune-modulating properties. Used for infections, biofilm disruption, and wound healing.
May reduce inflammatory markers and WBC if used for active infection. May modulate CRP. No direct effect on hormones, lipids, or liver enzymes. Primarily acts on innate immune system and microbial membranes.
Compound Guide
Structure: 37-amino acid cationic amphipathic peptide. The only known human cathelicidin. Naturally produced by neutrophils, epithelial cells, and macrophages.
Dosage:
- Standard titration: 50mcg/day (week 1) → increase by 50mcg/week → 200-400mcg/day maintenance
- Acute infection support: 200-400mcg/day for 4-8 weeks
- Maintenance: 100-200mcg 3x/week
Administration:
- SubQ injection, rotate sites
- 27-30g insulin syringe
- 8-12 week cycles (extendable to 16 weeks)
Key Notes:
- Broad-spectrum antimicrobial: effective against bacteria, fungi, and some viruses
- Disrupts bacterial biofilms — useful for chronic/resistant infections
- Modulates immune response: enhances neutrophil function, promotes wound healing
- Reduces LPS (endotoxin) binding to immune receptors — dampens sepsis-like inflammation
- Used by bodybuilders for persistent infections, post-surgical healing, and gut dysbiosis
- No direct effect on hormonal axes or metabolic markers
- Well tolerated — localised injection-site reactions are the most common side effect
- Reconstitute with bacteriostatic water, store refrigerated
Usage History
Frequently Asked Questions
Quick Reference
Category
Peptide
Half-Life
Unknown (acts locally and through immune modulation)
Detection Time
N/A